PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

ClinicalTrials.gov ID: NCT03218826

Public ClinicalTrials.gov record NCT03218826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

Study identification

NCT ID: NCT03218826
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 23 participants

Conditions and interventions

Conditions

Interventions

Docetaxel Drug
Laboratory Biomarker Analysis Other
PI3Kbeta Inhibitor AZD8186 Drug
Pharmacological Study Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 23, 2018
Primary completion: Jul 24, 2022
Completion: Oct 12, 2025
Last update posted: Apr 28, 2026

2018 – 2025

United States locations

U.S. sites: 8
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
UCHealth University of Colorado Hospital	Aurora	Colorado	80045	—
Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	Maryland	21287	—
National Cancer Institute Developmental Therapeutics Clinic	Bethesda	Maryland	20892	—
National Institutes of Health Clinical Center	Bethesda	Maryland	20892	—
Memorial Sloan Kettering Monmouth	Middletown	New Jersey	07748	—
Memorial Sloan Kettering Westchester	Harrison	New York	10604	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
M D Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03218826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 28, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03218826 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →